Does Health Net Cover Dupixent?

How Health Net Classifies Dupixent on Its Formulary

Health Net, a subsidiary of Centene Corporation operating primarily in California, Oregon, Washington, and Arizona, places Dupixent (dupilumab) on its specialty pharmacy tier across commercial HMO, PPO, and Medicaid managed-care plans. Specialty-tier placement means higher cost-sharing compared to preferred generics, but it does not mean the drug is excluded.

Dupilumab is a fully human monoclonal antibody targeting the interleukin-4 receptor alpha subunit (IL-4Rα), which blocks both IL-4 and IL-13 signaling [1]. The FDA first approved it in March 2017 for moderate-to-severe atopic dermatitis in adults [2]. Since then, the agency has expanded its label six times, most recently adding chronic obstructive pulmonary disease (COPD) with a type 2 inflammatory phenotype in September 2024 [3]. Health Net's formulary committees review each new indication separately, so coverage for one diagnosis does not guarantee coverage for another. Patients should confirm their specific plan's formulary listing through Health Net's online drug lookup tool or by calling the member services number on the back of their insurance card.

Because Health Net operates Medicaid managed-care plans in California (Medi-Cal) and other states, formulary rules differ between commercial and government lines. Medi-Cal plans generally follow the state's Contract Drug List, which includes dupilumab with prior authorization [4].

Prior Authorization Requirements

Nearly every Health Net plan requires prior authorization (PA) before approving Dupixent. The PA process typically takes 5 to 15 business days for a standard review, though urgent requests can be processed in 24 to 72 hours.

To obtain PA approval, prescribers must document the patient's diagnosis, disease severity, and treatment history. For atopic dermatitis, Health Net generally requires evidence that the patient has moderate-to-severe disease (Investigator Global Assessment [IGA] score of 3 or 4, or Eczema Area and Severity Index [EASI] score ≥ 16) and has tried and failed, or has a documented contraindication to, at least one topical corticosteroid of medium-to-high potency plus one topical calcineurin inhibitor such as tacrolimus or pimecrolimus [5]. Some plans also require trial of a systemic immunosuppressant like cyclosporine or methotrexate, though this varies by plan year.

For asthma indications, Health Net typically requires documentation of moderate-to-severe persistent asthma with an eosinophilic phenotype (blood eosinophils ≥ 150 cells/μL) or oral corticosteroid dependence, consistent with the Global Initiative for Asthma (GINA) Step 4/5 add-on biologic recommendations [6]. The prescriber must also show that the patient remains uncontrolled on medium-to-high-dose inhaled corticosteroids plus a long-acting beta-agonist.

For chronic rhinosinusitis with nasal polyps (CRSwNP), PA criteria usually require prior sinus surgery or contraindication to surgery, plus failure of intranasal corticosteroids [7]. Dupixent demonstrated a 24-point improvement in nasal congestion/obstruction severity and endoscopic polyp scores in the SINUS-24 trial (N=276) [8].

Step Therapy: What You Must Try First

Step therapy is the specific sequence of medications Health Net requires before authorizing Dupixent. This requirement exists because clinical guidelines recommend exhausting lower-cost therapies first.

For atopic dermatitis, the American Academy of Dermatology (AAD) guidelines position dupilumab as a systemic option after adequate trials of topical therapy [9]. Health Net's step therapy mirrors this approach. Patients typically need documented failure of: (1) a medium-to-high-potency topical corticosteroid used for at least 4 weeks, and (2) a topical calcineurin inhibitor or crisaborole (Eucrisa). Some Health Net plan documents also require trial and failure of phototherapy or one conventional systemic agent (methotrexate, cyclosporine, mycophenolate, or azathioprine).

The LIBERTY AD CHRONOS trial (N=740) showed that dupilumab 300 mg every two weeks plus topical corticosteroids produced EASI-75 responses in 69% of patients at week 16, compared with 23% on placebo plus topical corticosteroids [10]. This evidence supports dupilumab's use after topical therapy alone is insufficient.

For newer indications like eosinophilic esophagitis (EoE), step therapy requirements may include documented failure of proton pump inhibitor (PPI) therapy for at least 8 weeks. The key phase 3 trial in EoE (N=321) demonstrated histologic remission (≤6 eosinophils per high-power field) in 60% of dupilumab-treated patients versus 5% with placebo at 24 weeks [11].

What Dupixent Costs with Health Net Insurance

The wholesale acquisition cost (WAC) of Dupixent is approximately $3,546 per 300 mg syringe, translating to roughly $46,000 per year for the standard every-two-week adult dosing regimen. Your actual out-of-pocket cost with Health Net depends on your plan type, tier placement, and whether you have met your deductible.

Commercial HMO and PPO plans with Health Net typically assign Dupixent to Tier 4 (specialty) or Tier 5 (non-preferred specialty). Coinsurance on specialty tiers commonly ranges from 20% to 40% of the drug cost, though many plans cap specialty copays at $150 to $250 per fill. A plan with a $250 specialty copay cap and standard every-two-week dosing would cost a patient approximately $6,500 per year before any copay assistance.

Medi-Cal managed-care members enrolled in Health Net plans often face $0 to minimal cost-sharing for Dupixent after PA approval, consistent with Medicaid cost-sharing limits set by federal law. The Medicaid Drug Rebate Program requires manufacturers to provide rebates that reduce net costs to state programs [12].

Health Net Medicare Advantage plans (where available) place biologics on their Part B or Part D specialty tier. Medicare Part D specialty-tier cost-sharing is capped at 25% in the initial coverage phase under the Inflation Reduction Act's $2,000 annual out-of-pocket maximum that took effect January 2025 [13]. This cap significantly reduces the financial burden for Medicare beneficiaries using Dupixent.

Dupixent MyWay Copay Assistance and Patient Support

Sanofi and Regeneron's Dupixent MyWay program offers substantial financial support for eligible patients. The program has two main components.

The copay card is available to commercially insured patients (not eligible for those with government insurance including Medicare, Medicaid, or Tricare). Eligible patients may pay as little as $0 per Dupixent prescription, with the program covering up to $13 to 000 in annual copay costs [14]. The card is applied at the specialty pharmacy, and enrollment can be completed at dupixentmyway.com or by calling 1-844-DUPIXENT.

For uninsured patients or those who receive a coverage denial that survives the appeals process, Sanofi offers a patient assistance program (PAP) that provides Dupixent at no cost. Eligibility is income-based, generally requiring household income at or below 400% of the federal poverty level.

The program also provides nurse educator support, injection training, and insurance navigation services. Specialty pharmacies contracted with Health Net, such as Optum Specialty Pharmacy and Accredo, coordinate directly with Dupixent MyWay to apply copay card benefits at the point of dispensing. A study published in JAMA Dermatology found that manufacturer copay assistance programs reduced specialty medication abandonment rates by approximately 55% [15].

How to Appeal a Health Net Dupixent Denial

If Health Net denies your Dupixent prior authorization, you have the right to appeal. Understanding the process improves your chances of a successful outcome.

Start with an internal appeal. Health Net allows 180 days from the denial date to file an internal appeal for commercial plans. Your prescribing physician should submit a letter of medical necessity that includes: the specific diagnosis and ICD-10 code, disease severity scores (EASI, IGA, or equivalent), a list of all previously tried therapies with dates, doses, and reasons for discontinuation, and relevant clinical trial data supporting Dupixent for your condition.

The LIBERTY AD SOLO 1 and SOLO 2 trials (combined N=1,379) demonstrated that dupilumab 300 mg every two weeks achieved IGA 0/1 (clear or almost clear skin) in 36 to 38% of adult patients with moderate-to-severe atopic dermatitis at 16 weeks, compared with 8 to 10% on placebo [16]. Including this level of detail in appeal letters strengthens the case.

If the internal appeal fails, request an independent medical review (IMR). In California, the Department of Managed Health Care (DMHC) oversees IMR for Health Net HMO members. California's IMR process has historically overturned approximately 60% of health plan denials for specialty medications, according to DMHC annual reports [17].

For Health Net PPO members regulated by the California Department of Insurance (CDI), the external review process follows a similar pathway. Federal law under the Affordable Care Act guarantees the right to external review for all plan types [18].

FDA-Approved Indications and Expanding Coverage

Dupixent now carries six FDA-approved indications, and Health Net's coverage policies evolve as each new indication gains approval. Coverage status varies by indication.

Atopic dermatitis (approved March 2017, expanded to ages 6 months and older in 2022): This is the most commonly covered indication. The FDA approval was based on the LIBERTY AD clinical program, which enrolled over 2,500 patients across multiple phase 3 trials [16]. Health Net has well-established PA criteria for this indication.

Moderate-to-severe asthma (approved October 2018, expanded to ages 6+ in 2021): Covered with PA for patients meeting eosinophilic or oral corticosteroid-dependent criteria. The LIBERTY ASTHMA QUEST trial (N=1,902) showed dupilumab reduced severe exacerbations by 47.7% in the overall population and by 65.8% in patients with baseline eosinophils ≥ 300 cells/μL [19].

CRSwNP (approved June 2019): Covered with PA; typically requires prior surgical intervention or contraindication to surgery.

Eosinophilic esophagitis (approved May 2022): Coverage is becoming more consistent but may require additional peer-to-peer review with Health Net's medical directors [11].

Prurigo nodularis (approved September 2022): The PRIME and PRIME2 trials (combined N=311) showed significant itch reduction, with 60% of dupilumab-treated patients achieving a ≥ 4-point reduction in Worst Itch Numerical Rating Scale versus 18% placebo [20]. Coverage criteria may still be in flux for some Health Net plan years.

COPD with type 2 inflammation (approved September 2024): The BOREAS trial (N=939) demonstrated a 30% reduction in moderate-to-severe COPD exacerbations with dupilumab in patients with blood eosinophils ≥ 300 cells/μL [3]. Health Net PA criteria for this indication are still maturing, and some plans may not yet have formal coverage policies in place.

Dupixent vs. Other Covered Biologics and JAK Inhibitors

Health Net's formulary includes several alternatives to Dupixent, and understanding comparative coverage helps when navigating step therapy or appeal options.

For atopic dermatitis, JAK inhibitors represent the primary oral alternative. Abrocitinib (Cibinqo) and upadacitinib (Rinvoq) are both FDA-approved for moderate-to-severe atopic dermatitis in adults [21]. The Heads Up trial directly compared dupilumab with upadacitinib 30 mg, finding upadacitinib achieved EASI-75 in 71% of patients at week 16 versus 61% for dupilumab, though dupilumab had a more favorable safety profile, particularly regarding serious infections and herpes zoster reactivation [22]. Health Net may prefer dupilumab over JAK inhibitors given the FDA boxed warning on the JAK inhibitor class regarding serious infections, malignancy, cardiovascular events, and thrombosis [23].

For asthma, competing biologics include omalizumab (Xolair), mepolizumab (Nucala), benralizumab (Fasenra), and tezepelumab (Tezspire). Health Net's formulary positioning among these agents varies. A network meta-analysis published in The Lancet Respiratory Medicine found that dupilumab and tezepelumab showed the broadest efficacy across asthma phenotypes, while anti-IL-5 agents (mepolizumab, benralizumab) were most effective in patients with very high eosinophil counts (≥ 300 cells/μL) [24].

Tralokinumab (Adbry), which targets IL-13 alone, is another biologic option for atopic dermatitis. The ECZTRA trials showed EASI-75 rates of 25 to 33% with tralokinumab monotherapy at week 16 [25], numerically lower than dupilumab's performance in its registration trials, though direct head-to-head data are limited.

Tips for Maximizing Your Health Net Dupixent Coverage

Getting Dupixent approved and minimizing your costs requires a proactive approach across several steps.

Verify formulary status annually. Health Net updates its formulary each plan year (January 1 for most commercial plans). A drug covered this year may move tiers or gain new restrictions next year. Check the formulary before open enrollment if Dupixent is part of your treatment plan.

Ask your dermatologist or allergist to document everything. Detailed medical records showing disease severity scores, photographs, and a clear timeline of failed therapies make prior authorization requests and appeals far more likely to succeed. The AAD recommends that clinicians document specific validated outcome measures (EASI, SCORAD, BSA) at every visit for patients with moderate-to-severe atopic dermatitis [9].

Use the Dupixent MyWay copay card. If you have commercial insurance, this program can eliminate your copay entirely. Apply before your first fill, because the benefit does not apply retroactively to previous fills.

Request a peer-to-peer review. If PA is denied, your prescriber can request a phone consultation with Health Net's reviewing physician. These conversations allow the treating physician to explain clinical nuances that may not be apparent from chart notes alone. The American Medical Association has published guidance supporting peer-to-peer review as a standard part of the prior authorization process [26].

Track your out-of-pocket maximum. Once you reach your plan's annual out-of-pocket maximum, Health Net covers Dupixent at 100%. For patients using the drug year-round, this threshold is often reached within the first few months of the year, especially on high-deductible plans.

Consider plan selection during open enrollment. If you anticipate needing Dupixent, compare Health Net plans based on specialty-tier cost-sharing, annual out-of-pocket maximums, and whether the plan requires step therapy through systemic immunosuppressants. A plan with a lower out-of-pocket maximum may save thousands annually even if monthly premiums are higher.

Safety Considerations Relevant to Coverage Decisions

Health Net's coverage criteria reflect dupilumab's established safety profile, which is more favorable than many alternatives in the biologic and immunosuppressant space.

The most common adverse reactions in clinical trials were injection-site reactions (15% vs. 10% placebo), conjunctivitis (10% vs. 2% placebo in atopic dermatitis trials), and nasopharyngitis [16]. Conjunctivitis and other ocular surface events occur more frequently in atopic dermatitis patients than in those treated for asthma or CRSwNP. A meta-analysis of 3,197 patients across dupilumab trials found an overall conjunctivitis incidence of 8.6% in the atopic dermatitis population, compared with 0.5% in asthma trials [27].

Unlike JAK inhibitors, dupilumab does not carry FDA boxed warnings. It is not immunosuppressive in the traditional sense, because it targets type 2 inflammation (IL-4/IL-13) without broadly suppressing T-cell or B-cell function [1]. This distinction is clinically relevant. Rates of serious infections in dupilumab clinical trials were comparable to placebo (1.0% vs. 1.1% over 16 weeks in SOLO trials), and long-term extension studies through 3 years showed no new safety signals [28].

For Health Net's formulary committees, this safety advantage over systemic immunosuppressants like cyclosporine and methotrexate may support dupilumab's placement as the preferred biologic for atopic dermatitis, particularly in patients who are poor candidates for immunosuppression due to infection risk, hepatotoxicity concerns, or renal impairment.

Patients should complete age-appropriate vaccinations before initiating dupilumab, though inactivated vaccines can be administered during treatment. Live vaccines should be avoided unless the potential benefit outweighs the risk, per the prescribing information [2]. The CDC's Advisory Committee on Immunization Practices (ACIP) provides current vaccine schedules that clinicians should reference when planning dupilumab initiation [29].